Advertisement

Organisation › Details
Novo Group (Group)
Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo A/S is not a corporate strategic fund; Novo A/S invests for financial rather than strategic returns. Novo A/S is active in both Europe and North America. The Novo A/S venture investments are managed by a team of four Partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, Novo A/S annually invests approximately EUR 200 million through Novo Ventures, Novo Seeds, and Novo Growth Equity. In total Novo A/S has more than EUR 15 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S. *
![]() |
Start | 2004-09-13 existent |
![]() |
Industry | venture capital |
![]() |
Region | Denmark_oo |
Country | Denmark | |
Street | 19 Tuborg Havnevej | |
City | 2900 Hellerup | |
Tel | +45-3527-6500 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2025-03-16 |
Advertisement

More documents for Novo Group (Group)
- [1] Augustine Therapeutics N.V.. (3/24/25). "Press Release: Augustine Therapeutics Raises Oversubscribed EUR 78 Million / USD 85 Million Series A Financing Round". Leuven....
- [2] Coave Therapeutics (Horama S.A.). (1/9/25). "Press Release: Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines". Paris....
- [3] Kivu Bioscience. (10/28/24). "Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates". San Francisco, CA....
- [4] NanoVation Therapeutics Inc.. (9/18/24). "Press Release: NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases". Vancouver, BC....
- [5] Asceneuron S.A.. (7/16/24). "Press Release: Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases". Lausanne & San Francisco, CA....
- [6] Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London....
- [7] Single Use Support GmbH. (5/15/24). "Press Release: Novo Holdings Acquires Majority Stake in Single Use Support". Kufstein....
- [8] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
- [9] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....
- [10] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top